Investing.com - Harvard Bioscience (NASDAQ: HBIO) reported first quarter EPS of $0.040, $0.01 worse than the analyst estimate of $0.050. Revenue for the quarter came in at $28.2M versus the consensus estimate of $29.1M.
Harvard Bioscience's stock price closed at $4.110. It is down -21.260% in the last 3 months and up 65.730% in the last 12 months.
Harvard Bioscience saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Harvard Bioscience's stock price’s past reactions to earnings here.
According to InvestingPro, Harvard Bioscience's Financial Health score is "good performance".
Check out Harvard Bioscience's recent earnings performance, and Harvard Bioscience's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar